NEU 3.50% $14.05 neuren pharmaceuticals limited

Just 2 final items that should be read in conjunction with the...

  1. 2,899 Posts.
    lightbulb Created with Sketch. 607
    Just 2 final items that should be read in conjunction with the above post:
    *Daybue Q2 2024 sales should not be affected by seasonal factors.This was the indicated reason for the revenue guidance shortfall in the previous quarter.
    *It is worth noting that Q4 2023 Daybue revenue was already $87M.This number helps to put estimates a bit higher than this into some sort of perspective.
    Kens
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.